Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.
Cardiologists at Henry Ford Hospital in Detroit have successfully performed the country’s first implantation of the Neovasc Reducer—a stainless steel, hourglass-shaped heart mesh designed to alleviate difficult angina—the hospital announced in a statement Sept. 26.
Twenty-three hospitals from across Arkansas have joined the Arkansas Heart Attack Registry (AHAR), a collaborative effort to reduce the impact of myocardial infarctions in the state, THV 11 reported this week.
Biopharmaceutical company Amarin this week announced the topline results of its REDUCE-IT trial, a global study that achieved 25 percent cardiovascular risk reduction in a population of 8,179 statin-treated adults with the daily use of Vascepa, also known as icosapent ethyl.
A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego.
Resolute Onyx, a polymer-coated zotarolimus-eluting stent, has been proven safe and effective in an all-comer population of more than 2,000 heart patients, according to late-breaking results of the BIONYX trial.
The proportion of percutaneous coronary interventions (PCIs) performed in nonagenarians has more than doubled in the last decade in the United States, offering a significant survival benefit for those deemed healthy enough for the procedure, according to a study published online Sept. 17 in JACC: Cardiovascular Interventions.
Despite having the highest burden of cardiovascular disease in the U.S. and averaging more comorbidities than white patients, blacks are less likely to receive guideline-concordant care after a non-ST-segment elevation myocardial infarction (NSTEMI), researchers reported this week.
The prevalence of acute myocardial infarction (AMI) in the heart transplant (HT) population is “very low,” according to research published in the current online edition of the American Journal of Cardiology, but HT patients who do suffer a heart attack are more likely to experience longer hospital stays, higher 30-day readmission rates and greater in-hospital morbidities.
ST-segment elevation myocardial infarction (STEMI) patients have better odds of survival if emergency medical services (EMS) personnel alert the hospital where the patient will be arriving ahead of time, according to a study published Sept. 17 in JACC: Cardiovascular Interventions.
Despite overall advances in healthcare and targeted initiatives to address disparities in care, black patients and those with lower socioeconomic status tend to have worse outcomes for a range of conditions in the U.S. However, based on a recent analysis published in JAMA Network Open, hospital-level differences don’t explain the phenomenon.